This Frost & Sullivan 2026 Bluebook provides a comprehensive analysis of the global and Chinese antibody therapeutics industry. It covers market scale, technology evolution, and supply chain localization, highlighting key enablers like Cyagen to offer strategic guidance for stakeholders.

This brochure details Cyagen's one-stop Adeno-Associated Virus (AAV) solutions tailored for gene therapy, neuroscience, ophthalmology, and metabolic disease research. This brochure highlights our high-titer in-stock products and custom AAV packaging services. Discover our AI-engineered capsid variants capable of efficiently crossing the blood-brain barrier (BBB) for robust central nervous system (CNS) transduction.Accelerate your in vivo disease modeling and drug evaluation workflows.

JPM 2026 Insights by Cyagen: AI Transformation, Globalization 2.0, and Emerging Innovations in Core Modalities from Next-Gen ADCs to Degrader-Antibody Conjugates (DACs)

This white paper highlights Cyagen’s One-Stop Ophthalmology CRO Solutions, an end-to-end platform providing specialized HUGO-GT humanized models, 90%-success-rate surgical injections, and comprehensive efficacy evaluations to support every stage of ocular gene therapy development and IND filings.

This white paper aims to systematically analyze the current status and trends of the global and Chinese BsAb markets, explore key technological bottlenecks in depth, and introduce how Cyagen Biosciences leverages its HUGO-Ab™ series of fully human antibody mice.

This brochure details Cyagen's strong technological capabilities and proprietary TurboKnockout® ES targeting technology to generate the next-generation HUGO-Ab™ Humanized Antibody Mouse. These mice carry a complete set of human immunoglobulin genes and can produce fully human antibodies with high affinity and low immunogenicity in vivo.